These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 3940737)

  • 1. Effect of streptokinase on fibrinogen and related proteins in plasma.
    Bowie LJ; Kinney R; Vye M; Eckert B; Kwaan HC
    Clin Chem; 1986 Jan; 32(1 Pt 1):67-70. PubMed ID: 3940737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological effects of the administration of an equimolar streptokinase-plasminogen complex in man.
    Verstraete M; Vermylen J; Holleman W; Barlow GH
    Thromb Res; 1977 Aug; 11(2):227-36. PubMed ID: 905974
    [No Abstract]   [Full Text] [Related]  

  • 3. The thrombolytic activity of streptokinase in the rabbit.
    English PD; Smith RA; Dupe RJ; Green J; Hibbs MJ
    Thromb Haemost; 1981 Aug; 46(2):535-7. PubMed ID: 7302893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ON THE COMBINED ADMINISTRATION OF STREPTOKINASE AND PANCREATIC TRYPSIN INHIBITOR.
    VERSTRAETE M; VERMYLEN J; VERMYLEN C; DEVREKER RA
    Thromb Diath Haemorrh; 1964 Dec; 12():391-5. PubMed ID: 14254698
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of thrombosis by sequential therapy with ancrod followed by streptokinase. Clinical pharmacology and rheology.
    Forbes CD; Barbenell J; Prentice CR
    Haemostasis; 1976; 5(6):348-54. PubMed ID: 1017726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinogen degradation products in plasma following induced hyperfibrinolysis.
    Chek JB; Panchenko NI
    East Afr Med J; 2000 Apr; 77(4):217-20. PubMed ID: 12858907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of fibrin-fibrinogenolysis on the determination of the fibrinogen content and fibrin-fibrinogen degradation products (FDP) by means of the fibrin polymerization time (FPT test)].
    Vorlová Z; Dyr IE
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1979; 106(5-6):967-70. PubMed ID: 94893
    [No Abstract]   [Full Text] [Related]  

  • 8. The formation of a fibrinogen-activator complex by the action of streptokinase.
    Chesterman CN; Cederholm-Williams SA; Allington MJ; Sharp AA
    Thromb Res; 1977 Mar; 10(3):421-30. PubMed ID: 854878
    [No Abstract]   [Full Text] [Related]  

  • 9. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
    Hare TR; Gardell SJ
    Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proceedings: Fibrinolysis versus fibrinogenolysis: the specificity of human vascular activator (VA) as compared to urokinase (UK) and streptokinase (SK).
    Lipinski B; Gurewich V; Hyde E
    Thromb Diath Haemorrh; 1975 Sep; 34(1):351. PubMed ID: 1188799
    [No Abstract]   [Full Text] [Related]  

  • 11. Proteolysis of fibrinogen in healthy volunteers following major and minor vivo plasminogen activation.
    Prowse CV; Dawes J; Lane DA; Ireland H; Knight I
    Thromb Res; 1982 Jul; 27(1):91-7. PubMed ID: 6750837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theoretic and practical considerations on laboratory monitoring of thrombolytic therapy.
    Conard J; Samama MM
    Semin Thromb Hemost; 1987 Apr; 13(2):212-22. PubMed ID: 3114887
    [No Abstract]   [Full Text] [Related]  

  • 13. Evidence that fibrin(ogen) degradation products (FDP) are adequately quantified in citrated plasma defibrinated at low pH.
    Godal HC; Hamborg T
    Scand J Haematol; 1984 Jan; 32(1):46-8. PubMed ID: 6695150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequence of fibrinogen proteolysis and platelet release after intrauterine infusion of hypertonic saline.
    Nossel HL; Wasser J; Kaplan KL; LaGamma KS; Yudelman I; Canfield RE
    J Clin Invest; 1979 Nov; 64(5):1371-8. PubMed ID: 500818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A functional plasminogen assay utilizing the potentiating effect of fibrinogen to correct for the overestimation of plasminogen in pathological plasma samples.
    Gram J; Jespersen J
    Thromb Haemost; 1985 Apr; 53(2):255-9. PubMed ID: 4024036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products.
    Prentice CR; Hampton KK; Grant PJ; Nelson SR; Nieuwenhuizen W; Gaffney PJ
    Br J Haematol; 1993 Feb; 83(2):276-81. PubMed ID: 8457476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
    Theiss W; Asbeck F; Kriessmann A; Trübestein G; Knoch K; de Swart CA; Marbert GA; van de Loo JC
    Thromb Haemost; 1983 Oct; 50(3):664-8. PubMed ID: 6196852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinolytic effects of intracoronary streptokinase administration in patients with acute myocardial infarction and coronary insufficiency.
    Cowley MJ; Hastillo A; Vetrovec GW; Fisher LM; Garrett R; Hess ML
    Circulation; 1983 May; 67(5):1031-8. PubMed ID: 6831667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evaluation of plasmin and streptokinase activator complexes in a new rabbit model of venous thrombosis.
    Dupe RJ; English PD; Smith RA; Green J
    Thromb Haemost; 1981 Aug; 46(2):528-34. PubMed ID: 6458112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical comparison of intermittent streptokinase and intermittent streptokinase plasminogen therapy.
    Barlow GH; Kakkar VV; Bentley PG; Chan PS; Jones NA; Mistry FD
    Thromb Res; 1979; 15(1-2):135-42. PubMed ID: 483271
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.